Keryx Biopharmaceuticals (NASDAQ:KERX) at a glance


Dallas, Texas 09/20/2013 (Financialstrend) – In Thursday’s trading session, Keryx Biopharmaceuticals (NASDAQ:KERX) stock dropped by 1.21%. The opening price of the shares was $9.90 which climbed to an intraday high of $9.99 and closed at $9.78. Approximately 1.22 million shares exchanged hands in Thursday’s trading. The average volume of shares traded over a period of 30 days was 1.47 million. The 52-week low of the shares is $2.23 while the 52-week high is $10.03. Keryx Biopharmaceuticals (NASDAQ:KERX) has a market capitalization of $800.16 million.

About the company

Keryx Biopharmaceuticals (NASDAQ:KERX) is a bio-pharmaceutical company. It focuses on acquiring, developing and commercializing pharmaceutical products that are used to treat renal disease and cancer. It is developing an oral anti cancer-agent, KRX-0401 that inhibits Akt-activation in the phosphoinositide-3 kinase pathway. It also affects numerous other main signal-transduction pathways, such as the Jun-N terminal kinases pathway. All these pathways are associated with programmed-cell death, cell-growth, cell-differentiation and survival. KRX-0401 is currently in Phase III clinical-development for refractory advanced-colorectal cancer as well as refractory/relapsed multiple myeloma.

It is also in Phase-I and Phase-II clinical-development for some other tumor types. The company is also developing a ferric iron-based oral compound, Zerenex.  It is able to bind itself to phosphate that is in the gastrointestinal tract and it forms non-absorbable complexes. Zerenex is currently in Phase-III clinical development in the U.S, under an SPA or special protocol assessment, as a treatment in hyperphosphatemia in patients suffering from end-stage renal disease and are on dialysis.

In 2011 April 2011, Keryx Biopharmaceuticals (NASDAQ:KERX) reported its final dataset from the Phase3 short-term study. Zerenex is also in Phase 3 development by Torii and JT in Japan. In 2011 May, the company announced that it had received positive Scientific Advice from the EMA for Zerenex development in managing and controlling serum-phosphorus in ESRD patients who are undergoing dialysis.